PolTREG announces that the China National Intellectual Property Administration has issued a conditional decision to grant a patent to AZTherapies for the invention titled “CAR-Treg-based therapies for treating neurodegenerative diseases”.
PolTREG holds the exclusive global license for these innovative cellular therapies across all indications.
Completion of the procedure is subject only to payment of the required administrative fee within the statutory deadline.
The CAR-Treg neurodegeneration program is PolTREG’s most advanced next-generation therapy project, supported by encouraging in vivo preclinical data.
The project is already protected by patents in Australia, the United States, South Korea, and Japan.
